Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting [TheStreet.com]
Genprex, Inc. (GNPX)
Last genprex, inc. earnings: 11/14 12:08 pm
Check Earnings Report
Company Research
Source: TheStreet.com
PR Newswire AUSTIN, Texas, April 22, 2026 AUSTIN, Texas April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer. "We are pleased to be selected for publication at the 2026 ASCO Annual Meeting, one of the leading medical meetings for physicians and oncology professionals caring for people with cancer," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are also excited t
Show less
Read more
Impact Snapshot
Event Time:
GNPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GNPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GNPX alerts
High impacting Genprex, Inc. news events
Weekly update
A roundup of the hottest topics
GNPX
News
- Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual MeetingPR Newswire
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy [TheStreet.com]TheStreet.com
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyPR Newswire
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting [TheStreet.com]TheStreet.com
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingPR Newswire
GNPX
Sec Filings
- 4/21/26 - Form 8-K
- 4/17/26 - Form PRE
- 4/15/26 - Form 4
- GNPX's page on the SEC website